Novasecta defines European MidPharmas to be R&D-based integrated pharmaceutical companies with annual revenues of between €50m and €5bn. Our consulting work in this sector has given us a uniquely powerful understanding of how this tremendously diverse group of companies can survive and thrive. In this annual report we share some of our insights into their health. Through this analysis we point to a focused and entrepreneurial future for the entire industry that goes beyond an industry dynamic driven by Big Pharma and small biotechs.
What our clients
say about us
We have worked collaboratively with Novasecta over many years across a range of strategic topics. I have particularly valued how they really understand and care about our business, and how they manage to apply their deep industry insights to our context. This has brought my Management Team and Board to clarity and alignment on practical strategic moves at important moments in our evolution as a company.CEO – Biotech